Company Description
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.
It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period.
It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products.
The company was incorporated in 2006 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 20, 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2,000 |
| CEO | Quentin S. Blackford |
Contact Details
Address: 699 8th Street, Suite 600 San Francisco, California 94103 United States | |
| Phone | 415-632-5700 |
| Website | irhythmtech.com |
Stock Details
| Ticker Symbol | IRTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001388658 |
| CUSIP Number | 450056106 |
| ISIN Number | US4500561067 |
| Employer ID | 20-8149544 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Quentin S. Blackford | President, Chief Executive Officer and Director |
| Brice Bobzien CPA | Chief Financial Officer |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical and Scientific Officer and Executive Vice President of Product Innovation |
| Patrick Michael Murphy J.D. | Chief Business and Legal Officer |
| Douglas J. Devine | Executive Advisor |
| Chad M. Patterson | Chief Commercial Officer |
| Marc Rosenbaum | Senior Vice President of Finance and Chief Accounting Officer |
| Mark J. Day Ph.D. | Chief Technology Officer |
| Daniel G. Wilson | Executive Vice President of Corporate Development and Investor Relations |
| Sumi Shrishrimal | Executive Vice President and Chief Risk Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | ARS | Filing |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |